ReviewOncology letters2026
Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a malignant solid tumor with limited treatment options, particularly for advanced tumor stages. Chimeric antigen receptor (CAR)-T therapy has been successful in treating hematological malignancies; however, its efficacy in solid tumors remains suboptimal due to the complex tumor microenvironment (TME). The TME in GC comprises diverse signaling molecules and cellular components, including fibroblasts, immune cells and stromal proteins; these components can support tumor growth, invasion and immune evasion. In the GC TME, the dynamic interactions between cytokines, chemokines, growth factors and their receptors can foster chronic inflammation and immunosuppression, thereby facilitating tumor progression, metastasis and therapeutic resistance. The present review provides novel insights into the understanding and functional impact of cell-chemokine interaction networks in GC, highlighting the therapeutic implications of chemokines in immunotherapy. In addition, current related research areas are outlined and advances in therapeutic strategies targeting key chemokine signaling pathways are discussed. By providing critical insights into TME reprogramming and immunomodulation, the current study aims to encourage the strategic application of chemokine engineering in next-generation CAR-T immunotherapy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.